Literature DB >> 19228980

Rodent habenulo-interpeduncular pathway expresses a large variety of uncommon nAChR subtypes, but only the alpha3beta4* and alpha3beta3beta4* subtypes mediate acetylcholine release.

Sharon R Grady1, Milena Moretti, Michele Zoli, Michael J Marks, Alessio Zanardi, Luca Pucci, Francesco Clementi, Cecilia Gotti.   

Abstract

Recent studies suggest that the neuronal nicotinic receptors (nAChRs) present in the habenulo-interpeduncular (Hb-IPn) system can modulate the reinforcing effect of addictive drugs and the anxiolytic effect of nicotine. Hb and IPn neurons express mRNAs for most nAChR subunits, thus making it difficult to establish the subunit composition of functional receptors. We used immunoprecipitation and immunopurification studies performed in rat and wild-type (+/+) and beta2 knock-out (-/-) mice to establish that the Hb and IPn contain significant beta2* and beta4* populations of nAChR receptors (each of which is heterogeneous). The beta4* nAChR are more highly expressed in the IPn. We also identified novel native subtypes (alpha2beta2*, alpha4beta3beta2*, alpha3beta3beta4*, alpha6beta3beta4*). Our studies on IPn synaptosomes obtained from +/+ and alpha2, alpha4, alpha5, alpha6, alpha7, beta2, beta3, and beta4(-/-) mice show that only the alpha3beta4 and alpha3beta3beta4 subtypes facilitate acetylcholine (ACh) release. Ligand binding, immunoprecipitation, and Western blotting studies in beta3(-/-) mice showed that, in the IPn of these mice, there is a concomitant reduction of ACh release and alpha3beta4* receptors, whereas the receptor number remains the same in the Hb. We suggest that, in habenular cholinergic neurons, the beta3 subunit may be important for transporting the alpha3beta4* subtype from the medial habenula to the IPn. Overall, these studies highlight the presence of a wealth of uncommon nAChR subtypes in the Hb-IPn system and identify alpha3beta4 and alpha3beta3beta4, transported from the Hb and highly enriched in the IPn, as the subtypes modulating ACh release in the IPn.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19228980      PMCID: PMC2680386          DOI: 10.1523/JNEUROSCI.5121-08.2009

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  69 in total

1.  Localization of nAChR subunit mRNAs in the brain of Macaca mulatta.

Authors:  Z Y Han; N Le Novère; M Zoli; J A Hill; N Champtiaux; J P Changeux
Journal:  Eur J Neurosci       Date:  2000-10       Impact factor: 3.386

2.  Incorporation of the beta3 subunit has a dominant-negative effect on the function of recombinant central-type neuronal nicotinic receptors.

Authors:  Steven Broadbent; Paul J Groot-Kormelink; Paraskevi A Krashia; Patricia C Harkness; Neil S Millar; Marco Beato; Lucia G Sivilotti
Journal:  Mol Pharmacol       Date:  2006-07-05       Impact factor: 4.436

3.  Editorial--modeling negative symptoms: what's missing?

Authors:  Paul D Shepard
Journal:  Schizophr Bull       Date:  2006-05-17       Impact factor: 9.306

4.  18-Methoxycoronaridine acts in the medial habenula and/or interpeduncular nucleus to decrease morphine self-administration in rats.

Authors:  Stanley D Glick; Ruby L Ramirez; Jacklyn M Livi; Isabelle M Maisonneuve
Journal:  Eur J Pharmacol       Date:  2006-03-24       Impact factor: 4.432

5.  Nicotinic acetylcholine receptor subunit mRNA expression and channel function in medial habenula neurons.

Authors:  E B Sheffield; M W Quick; R A Lester
Journal:  Neuropharmacology       Date:  2000-10       Impact factor: 5.250

6.  Facilitation of glutamatergic neurotransmission by presynaptic nicotinic acetylcholine receptors.

Authors:  R Girod; N Barazangi; D McGehee; L W Role
Journal:  Neuropharmacology       Date:  2000-10       Impact factor: 5.250

7.  Stoichiometry of human recombinant neuronal nicotinic receptors containing the b3 subunit expressed in Xenopus oocytes.

Authors:  J P Boorman; P J Groot-Kormelink; L G Sivilotti
Journal:  J Physiol       Date:  2000-12-15       Impact factor: 5.182

8.  High resolution spatial mapping of nicotine action using pharmacologic magnetic resonance imaging.

Authors:  Ji-Kyung Choi; Joseph B Mandeville; Y Iris Chen; Young R Kim; Bruce G Jenkins
Journal:  Synapse       Date:  2006-08       Impact factor: 2.562

9.  Identification of a novel nicotinic binding site in mouse brain using [(125)I]-epibatidine.

Authors:  P Whiteaker; M Jimenez; J M McIntosh; A C Collins; M J Marks
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

10.  18-MC acts in the medial habenula and interpeduncular nucleus to attenuate dopamine sensitization to morphine in the nucleus accumbens.

Authors:  Olga D Taraschenko; Joseph M Shulan; Isabelle M Maisonneuve; Stanley D Glick
Journal:  Synapse       Date:  2007-07       Impact factor: 2.562

View more
  113 in total

1.  AT-1001: a high affinity and selective α3β4 nicotinic acetylcholine receptor antagonist blocks nicotine self-administration in rats.

Authors:  Lawrence Toll; Nurulain T Zaveri; Willma E Polgar; Faming Jiang; Taline V Khroyan; Wei Zhou; Xinmin Simon Xie; Gregory B Stauber; Matthew R Costello; Frances M Leslie
Journal:  Neuropsychopharmacology       Date:  2012-01-25       Impact factor: 7.853

2.  Novel α3β4 nicotinic acetylcholine receptor-selective ligands. Discovery, structure-activity studies, and pharmacological evaluation.

Authors:  Nurulain Zaveri; Faming Jiang; Cris Olsen; Willma Polgar; Lawrence Toll
Journal:  J Med Chem       Date:  2010-10-27       Impact factor: 7.446

3.  Modulation of recombinant, α2*, α3* or α4*-nicotinic acetylcholine receptor (nAChR) function by nAChR β3 subunits.

Authors:  Bhagirathi Dash; Minoti Bhakta; Yongchang Chang; Ronald J Lukas
Journal:  J Neurochem       Date:  2012-03-14       Impact factor: 5.372

4.  Adolescent nicotine exposure transiently increases high-affinity nicotinic receptors and modulates inhibitory synaptic transmission in rat medial prefrontal cortex.

Authors:  Danielle S Counotte; Natalia A Goriounova; Milena Moretti; Marek T Smoluch; Hubertus Irth; Francesco Clementi; Anton N M Schoffelmeer; Huibert D Mansvelder; August B Smit; Cecilia Gotti; Sabine Spijker
Journal:  FASEB J       Date:  2012-02-03       Impact factor: 5.191

5.  Role of α7- and β4-containing nicotinic acetylcholine receptors in the affective and somatic aspects of nicotine withdrawal: studies in knockout mice.

Authors:  Astrid K Stoker; Berend Olivier; Athina Markou
Journal:  Behav Genet       Date:  2011-10-19       Impact factor: 2.805

6.  The β3 subunit of the nicotinic acetylcholine receptor: Modulation of gene expression and nicotine consumption.

Authors:  Helen M Kamens; Jill Miyamoto; Matthew S Powers; Kasey Ro; Marissa Soto; Ryan Cox; Jerry A Stitzel; Marissa A Ehringer
Journal:  Neuropharmacology       Date:  2015-08-25       Impact factor: 5.250

7.  α9- and α7-containing receptors mediate the pro-proliferative effects of nicotine in the A549 adenocarcinoma cell line.

Authors:  Vanessa Mucchietto; Francesca Fasoli; Susanna Pucci; Milena Moretti; Roberta Benfante; Annalisa Maroli; Simona Di Lascio; Cristiano Bolchi; Marco Pallavicini; Cheryl Dowell; Michael McIntosh; Francesco Clementi; Cecilia Gotti
Journal:  Br J Pharmacol       Date:  2017-09-08       Impact factor: 8.739

Review 8.  Nicotinic acetylcholine receptors and nicotine addiction: A brief introduction.

Authors:  Ruthie E Wittenberg; Shannon L Wolfman; Mariella De Biasi; John A Dani
Journal:  Neuropharmacology       Date:  2020-07-29       Impact factor: 5.250

9.  Crucial role of nicotinic α5 subunit variants for Ca2+ fluxes in ventral midbrain neurons.

Authors:  Miriam Sciaccaluga; Claudia Moriconi; Katiuscia Martinello; Myriam Catalano; Isabel Bermudez; Jerry A Stitzel; Uwe Maskos; Sergio Fucile
Journal:  FASEB J       Date:  2015-04-24       Impact factor: 5.191

10.  [¹²⁵I]AT-1012, a new high affinity radioligand for the α3β4 nicotinic acetylcholine receptors.

Authors:  Jinhua Wu; David C Perry; James E Bupp; Faming Jiang; Willma E Polgar; Lawrence Toll; Nurulain T Zaveri
Journal:  Neuropharmacology       Date:  2013-10-03       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.